LLY240705P840000
- 0.01
- -0.10-90.91%
Eli Lilly and Co Newsroom
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
The Trader: Conagra Took a GLP-1 Hit. Why Its Stock Is Worth a Look. -- Barron's
By Paul R. La Monica Ozempic and other popular injectable GLP-1 drugs aren't just helping dieters shed pounds. They're also leading to share price losses for top food stocks. Take a look at Conagra B
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE:LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.What's Happening: Morgan Stanley has maintained its Overweight rating on Eli Lill
Express News | Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and othe
Express News | 'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Eli Lilly Remains an Equities Outlier
Smart Money Is Betting Big In LLY Options
High-rolling investors have positioned themselves bearish on Eli Lilly and Co (NYSE:LLY), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga
Express News | Morgan Stanley Maintains Overweight on Eli Lilly and Co, Maintains $1023 Price Target
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/05/2024 14.02% Morgan Stanley $1023 → $1023 Maintains Overweight 07/03/2024 11.57% BMO Capital $1001 →
Here's How Much $100 Invested In Eli Lilly and Co 15 Years Ago Would Be Worth Today
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 11.54% on an annualized basis producing an average annual return of 24.56%. Currently, Eli Lilly and Co has a market c
Today's Analyst Rating | Microsoft Price Target Raised to $480 by Raymond James, Itau Unibanco Upgrades Apple to Hold
Jul 4, Wall Street analysts have updated their stock ratings today including $Microsoft(MSFT.US)$ and $Apple(AAPL.US)$.
What Trump 2.0 or Biden 2.0 Could Mean for the Stock Market
President Biden is publicly showing no signs of stepping back and held a virtual meeting with governors on Wednesday to try to reassure them he's up to the job.
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
Shares of obesity drugmakers dipped on Wednesday after a study showed that patients who received Novo Nordisk’s NVO semaglutide, which is marketed as Wegovy (for obesity) and Ozempic (for diabetes), could develop a rare blinding eye disorder.
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
These Funds Made Heady Gains. Thank Nvidia.
Which fund held Nvidia—and how big their stake was—went a long way to determining winners and losers in the quarter. Here's who benefited, and who missed the boat.
BMO: Eli Lilly and Co's Alzheimer's drug is expected to generate revenue of $7.1 billion, which is better than Biogen's competitor.
According to BMO reports, eli lilly and co's newly approved Alzheimer's drug donanemab could bring in peak sales of up to $7.1 billion for the company.
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$8.1 Million in Common Stock
$Eli Lilly and Co(LLY.US)$ 10% Shareholder LILLY ENDOWMENT INC sold 8,848 shares of common stock on Jul 3, 2024 at an average price of $915.309 for a total value of $8.1 million.Source: Announcement W